|
|
|
|
| |
TAKE THIS POLL |
|
|
- Genentech Provides Update on Studies of Investigational Biooncology Agents to Be Presented at the American 16 May 2008 02:16 GMT
... the 30 enrolled patients showed a response to single-agent ABT-263. Two patients with bulky chronic lymphocytic leukemia (CLL), one patient with bulky CLL/small lymphocytic lymphoma (SLL), one patient with follicular lymphoma ...
- Abbott to Present Data on Novel Cancer Treatments at American Society of Clinical Oncology Annual Me 16 May 2008 02:02 GMT
... leading to the formation and growth of tumors. Preclinical studies showed promising activity against chronic lymphocytic leukemia (CLL), lymphomas and small cell lung cancer -- Phase I/II trials are currently underway ...
- Abbott to Present Data on Novel Cancer Treatments at American Society of Clinical Oncology Annual Meeting 16 May 2008 01:35 GMT
... leading to the formation and growth of tumors. Preclinical studies showed promising activity against chronic lymphocytic leukemia (CLL), lymphomas and small cell lung cancer -- Phase I/II trials are currently underway ...
- Genentech Provides Update on Studies of Investigational Biooncology Agents to Be Presented at the American Society of Clinical Oncology Meeting 16 May 2008 01:15 GMT
... the 30 enrolled patients showed a response to single-agent ABT-263. Two patients with bulky chronic lymphocytic leukemia (CLL), one patient with bulky CLL/small lymphocytic lymphoma (SLL), one patient with follicular lymphoma ...
- /C O R R E C T I O N -- Lentigen Corporation/ 15 May 2008 19:45 GMT
... (EBV)-related diseases, with Dr. Rimas Orentas, Ph.D. Associate Professor, Medical College of Wisconsin -- Chronic lymphocytic leukemia (CLL), with Dr. Wiestner M.D./Ph.D., Principal Investigator, National Cancer Institute rather than -- Melanoma, ...
- Lentigen Corporation Receives Four Research Grants From the National Institutes of Health 15 May 2008 14:25 GMT
... Epstein-Barr virus (EBV)-related diseases, with Adrian Wiestner, M.D./Ph.D., Principal Investigator, National Cancer Institute -- Chronic lymphocytic leukemia (CLL), also with Dr. Wiestner Together with its collaborators, Lentigen will develop lentiviral vectors ...
- A Gentler Option for Leukemia: Reduced-Intensity BMT 15 May 2008 04:45 GMT
... myelogenous leukemia or CML) accounts for about 4,400 new cases of leukemia each year. Chronic lymphocytic leukemia (also called chronic lymphoblastic leukemia or CLL) accounts for about 7,000 new cases of ...
- FDA releases a Follow-up to the November 14, 2007, Communication about the Ongoing Safety Review of Cefepime (marketed as Maxipime) 14 May 2008 23:07 GMT
... is a purine alkylator hybrid chemotherapy agent indicated for the treatment of patients with chronic lymphocytic leukemia (CLL). Artiss (fibrin sealant (human)) is a slow-setting fibrin sealant indicated for use in ...
- FDA Places Geron's GRNOPC1 IND on Clinical Hold 14 May 2008 20:58 GMT
... is a purine alkylator hybrid chemotherapy agent indicated for the treatment of patients with chronic lymphocytic leukemia (CLL). Artiss (fibrin sealant (human)) is a slow-setting fibrin sealant indicated for use in ...
- Mylan Launches Paroxetine Hydrochloride Extended-Release Tablets 14 May 2008 17:08 GMT
... is a purine alkylator hybrid chemotherapy agent indicated for the treatment of patients with chronic lymphocytic leukemia (CLL). Artiss (fibrin sealant (human)) is a slow-setting fibrin sealant indicated for use in ...
- Sosei Announces Outcome of Strategy Review 14 May 2008 15:12 GMT
... is a purine alkylator hybrid chemotherapy agent indicated for the treatment of patients with chronic lymphocytic leukemia (CLL). Artiss (fibrin sealant (human)) is a slow-setting fibrin sealant indicated for use in ...
- Daiichi Sankyo: Expansion of Business into Turkey and India 14 May 2008 00:10 GMT
... is a purine alkylator hybrid chemotherapy agent indicated for the treatment of patients with chronic lymphocytic leukemia (CLL). Artiss (fibrin sealant (human)) is a slow-setting fibrin sealant indicated for use in ...
- Angiotech appoints Hank McKinnell to its Board of Directors 14 May 2008 00:05 GMT
... is a purine alkylator hybrid chemotherapy agent indicated for the treatment of patients with chronic lymphocytic leukemia (CLL). Artiss (fibrin sealant (human)) is a slow-setting fibrin sealant indicated for use in ...
- Researchers Are Changing Leukemia Treatments and Outcomes 13 May 2008 04:53 GMT
... ...
- Newer Therapies Make Inroads Against Adult Leukemias 13 May 2008 04:53 GMT
... ...
- Bendamustine (Treanda): Alkylating agent approved for the treatment of chronic lymphocytic leukemia 13 May 2008 04:52 GMT
... ...
- Gritty Determination Sees Survivor Through 13 May 2008 04:37 GMT
... ...
- Second Chance For Leukemia Patients 13 May 2008 04:33 GMT
... ...
- Capt. Chemo takes message south 13 May 2008 04:33 GMT
... ...
- Seeking justice for veterans, By TOM LAVENTURE, Staff Writer 13 May 2008 00:47 GMT
... ...
1 - 25 of 57 next >
News by PR Newswire
|
| Tip of the day
Related Newsletters
Come and Visit
|
|
| | |